Prognostic analysis of DLBCL patients and the role of upfront ASCT in high-intermediate and high-risk patients

The role of autologous stem cell transplantation (ASCT) as a frontline treatment in patients with diffuse large B cell lymphoma (DLBCL) who are in their first remission has not been fully elucidated in the rituximab era. We analyzed 272 DLBCL patients who received 4–6 cycles of R-CHOP (rituximab, cy...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Ying, Wang, Hong, Jin, Song, Zheng, Jiajia, Huang, Man, Tang, Yaqiong, Jin, Zhengming, Qiu, Huiying, Tang, Xiaowen, Fu, Chengcheng, Han, Yue, Wu, De-Pei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5641203/
https://www.ncbi.nlm.nih.gov/pubmed/29069860
http://dx.doi.org/10.18632/oncotarget.17324

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5641203/
https://www.ncbi.nlm.nih.gov/pubmed/29069860
http://dx.doi.org/10.18632/oncotarget.17324

Ejemplares similares